Skip to main content
NCBI home page
Medicine logoLink to Medicine
. 2022 Dec 9;101(49):e32222. doi: 10.1097/MD.0000000000032222

Using network pharmacology and molecular docking verification to explore the mechanism of ursolic acid in the treatment of osteoporosis

Bowen Yang a, Qiuwen Zhu b, Xiaodong Wang c, Jingxin Mao c,d,*, Shuqing Zhou a,*
PMCID: PMC9750584  PMID: 36626454

Abstract

Whether ursolic acid is an effective drug in treatment of osteoporosis (OP) and how it exhibit activity effect on OP is unclear. To investigated the potential molecular mechanism of ursolic acid in the treatment of OP and figured out its possible mechanism is necessary. The target genes of ursolic acid were screened by using the database of traditional chinese medicine systems pharmacology, PubMed database and UniProt database. OP-related target genes were searched by GeneCards database, and utilized online mapping tool to obtain common target genes of component-disease. String database was used to construct a protein-protein interaction (PPI) network of component-disease common target genes and perform topological analysis to screen core target genes. DAVID database was performed gene ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis for component-disease shared target genes. Using the core target protein as the receptor and ursolic acid as the ligand, the molecular docking was performed using AutoDockVina 1.1.2 software. A total of 52 ursolic acid-related target genes and 4657 OP-related target genes were excavated, with a total of collective 43 target genes. The above-mentioned PPI network with shared target genes contains 43 nodes and 510 edges, with an average node degree value of 23.32. A total of 24 core target genes were obtained, mainly including tumor protein p53 (TP53), vascular endothelial growth factor A (VEGFA), interleukin-6 (IL6), tumor necrosis factor (TNF), caspase3 (CASP3), matrix metallo protein (MMP9), transcription factor AP-1 (JUN), activator of transcription 3 (STAT3), mitogen-activated protein kinase 8 (MAPK8), and prostaglandin endoperoxidase 2 (PTGS2), respectively. According to KEGG enrichment analysis, there are 126 treatment of OP signaling pathway were enriched. GO enrichment analysis revealed that 313 biological processes were identified. The molecular docking result showed that the binding energies were all lower than −5 kcal/mol, indicating strong binding activity to the protein by the 6 core target gene. The therapeutic effect of ursolic acid on OP may be achieved by regulating TP53, JUN, IL6, VEGFA, CASP3, and MAPK8 genes, respectively. It exhibits possible biological function in the treatment of OP mainly involve positive regulation of apoptotic process, response to drug, incytoplasm, cytosol, protein binding, identical protein binding. Its mechanism may related to multiple therapeutic targets and signaling pathways such as cancer pathway, hepatitis B, and TNF signaling pathway.

Keywords: molecular docking; molecular mechanism, network pharmacology; osteoporosis; ursolic acid

1. Introduction

Osteoporosis (OP) is an inflammatory metabolic disease with a complex occurrence and development process, which is closely related to multiple genes and signaling pathways in the body. With the increase of population growth and aging, the incidence of OP is also increasing year by year, which has become a major public health problem in the world.[1] There are currently 200 million women with OP in the world, and about 30% of the elderly over 50 years old have 1 or more fractures. The situation is very serious. In addition, the disease may also induce other diseases, causing a heavy economic burden to the patient’s family and society.[2] The elderly are the main patient population of OP. At present, most of the clinical drugs for the treatment of OP are chemical drugs that regulate bone metabolism, but they may cause a series of adverse reactions such as kidney damage, which limits their clinical application.[3] Since there are no obvious symptoms in the early stage of the disease, once it is diagnosed, it is relatively late, and even life-threatening, finally resulting in serious and irreversible consequences. OP belongs to the category of “bone atrophy” in the Traditional Chinese Medicine (TCM) which is to invigorate the kidney and replenish the essence, activate blood and remove blood stasis as the basic principle.[4] However, the relevant molecular mechanism of TCM treatment of OP has not been fully elucidated, which restricts the further transformation of related TCM theories to clinical practice. Most of the current new drug screening ideas focus on the targeted therapy and mechanism of drugs on a certain key protein and molecule. Ursolic acid has anti-oxidative,[5] anti-inflammatory,[6] anti-viral,[7] anti-tumor[8,9] and other effects, and is widely distributed in nature. Relevant studies have shown that ursolic acid may significantly improve kidney damage.[10] The TCM theory believes that kidney deficiency is the main pathogenesis of OP, advocates that the treatment of OP should be paralleled with the protection of renal function.[11] Therefore, according to the theory of “invigorating the kidney and strengthening bones” in TCM, ursolic acid may have a potential OP improvement effect. Network pharmacology is to use the achievements of computer science, molecular biology, pharmacy and other disciplines to carry out multi-gene, multi-target and multi-channel systematic research on the potential targets and pharmacological effects of TCM ingredients, which can provide information and new ideas for the modernization of TCM.[12] Molecular docking is a theoretical simulation method that predicts the binding mode and affinity of the receptor through the interaction between the receptor and the drug molecule.[13] Combining the network pharmacology method and molecular docking technology to preliminarily explore the potential targets and pathways of ursolic acid in the treatment of OP in the study. It may provided a basis for further elucidation of the molecular mechanism of ursolic acid in the treatment of OP.

2. Methods

2.1. Extraction of target genes of ursolic acid

The potential target proteins of ursolic acid were retrieved through the database of traditional chinese medicine systems pharmacology (https://old.tcmsp-e.com/tcmsp.php), and the potential target proteins of ursolic acid were retrieved from the PubMed database (https://pubmed.ncbi.nlm.nih.gov) for structural alignment. Through the UniProt database (https://www.uniprot.org), the proteins corresponding to the above targets were converted into human genes, and a database of ursolic acid monomer compounds and their target genes was constructed.

2.2. Screening of OP-related target genes

Using “osteoporosis” as the keyword, a human gene search was performed in the GeneCards database (https://www.genecards.org) to obtain the disease target genes of OP.

2.3. Screening of component-disease common target genes

The two groups of targets screened in 2.1 and 2.2 were entered into the online mapping tool (http://bioinformatics.psb.ugent.be/cgi-bin/liste/Venn/calculate_venn.htpl) to draw venn diagram for component-disease common target genes.

2.4. Construction and topology analysis of protein-protein interaction network of shared target genes

Import the common target genes of component-disease into the String database (https://string-db.org/cgi/input.pl), set the biological species as “homosapiens (Homo sapiens),” and construct proteins with common target genes -protein interaction relationship (PPI) network, and import the construction results into Cytoscape 3.8.0 software for visual display. In the visual network diagram, the common target gene is represented by a node. The darker the color and the larger the shape, the greater the degree of the corresponding target gene, that is, the more important the target gene is; the edge represents the common target gene. The thicker the line, the greater the combination score between target genes, that is, the more significant the correlation between target genes and target genes.[14] Topological analysis of the PPI network was performed with the help of the “networkanalyzer” tool in the Cystoscape 3.8.0 software. The median value of 3 parameters, including degree value, betweenness centrality, and closeness centrality, is used as the reference index. Among them, betweenness centrality represents the number of shortest paths passing through a node, the greater the betweenness centrality, the greater the influence of the node[15]; the closeness centrality represents the average distance between the node and other nodes in the network, and the closeness to the center, the higher the degree of nodes, the better the information flow[16]; the target gene with a degree value greater than the average degree value is selected as the core target gene, and the degree value, betweenness centrality and closeness centrality are all ranked. The topology analysis results of the top 10 core target genes are displayed.

2.5. Gene ontology functional annotation and KEGG pathway enrichment analysis

GO functional annotation and KEGG pathway enrichment analysis were performed on component-disease shared target genes using the DAVID database (https://david.ncifcrf.gov). Among them, GO functional annotation analysis mainly involves biological process (BP), molecular function (MF), cellular component (CC) functions. Set the species to “homosapiens” and the identifier to “official genesymbol (official name),” retain entries with a corrected P value less than .05, and sort them according to the corrected P value from small to large. Select the top 20 entries and import them into RStudio 3.6.3 software to visualize the enrichment results.

2.6. Component core target gene coding protein molecular docking test

Download the 3-dimensional structure of the protein encoded by the core target gene from the protein data bank database (https://www.rcsb.org), and save it in the “protein data bank” format as the protein receptor. Using AutoDockTools 1.5.6 to removes water molecules, separates proteins, adds non-polar hydrogen and other treatments to the protein receptor, calculates the gasteiger charge of its structure to ensure that the atoms follow the atomic type in autodock, and then saves it as a “pdbqt” format file. Download the 2-dimensional structure of ursolic acid from PubChem database (https://pubchem.ncbi.nlm.nih.gov), save it in “mol2” format, and utilized AutoDockTools 1.5.6 after hydrogenation, charging, detecting the central node of ligand molecule and searching and defining the rotatable bond, the software will save it as a “pdbqt” format file as the ligand. The receptor is set to be rigid and the ligand is set to be flexible, then Autodock vina 1.1.2 software was used for molecular docking of protein receptor encoded by core target gene and ursolic acid ligand. The binding ability of ligand and receptor is evaluated by binding energy. If the binding energy is less than 0, it means that ligand and receptor can spontaneously bind, and the smaller the value, the higher the binding activity.[17] Pymol 2.4.0 software was used for visual display of docking results finally.

3. Results

3.1. Screening results of target genes related to ursolic acid and OP

The molecular formula of ursolic acid is C30H48O3 (PubChem CID:64945) and its molecular weight is 498.737. Ursolic acid is a kind of triterpenoids in natural plants, the 2-dimensional structure of ursolic acid was presented in Figure 1. After searching, summarizing and deleting the duplicate, a total of 52 ursolic acid related target genes were obtained; 4657 OP related target genes were retrieved in genecards database, and 43 component disease target genes were obtained (Fig. 2).

Figure 1.

Figure 1.

Open in a new tab

The 2D structure of ursolic acid. 2D = two-dimensional.

Figure 2.

Figure 2.

Open in a new tab

Venn diagram of the common target gene screening of ursolic acid and OP. OP = osteoporosis.

3.2. Construction of PPI network of common target genes and screening results of core target genes

The PPI visualization network of component disease common target genes was shown in Figure 3. The network has 43 nodes and 510 edges, and the average node degree is 23.32. There are no isolated nodes in the network, and the connectivity between nodes is good, indicating that ursolic acid may play its role in the treatment of OP through multi-target collaborative regulation. The results of network topology analysis show that there are 24 core target genes which node degree value is greater than the average degree value (23.32). The top 10 core target genes with degree value, intermediate centrality and near centrality are TP53, VEGFA, IL6, TNF, caspase3 (CASP3), MMP9, JUN, STAT3, MAPK8, and PTGS2 respectively. The results of topology analysis are shown in Table 1.

Figure 3.

Figure 3.

Open in a new tab

Component-PPI visualization network diagram of disease common target genes. PPI = protein-protein interaction.

Table 1.

Topological analysis results of core target genes of ursolic acid in the treatment of OP.

Core target gene Degree value Betweenness centrality Closeness centrality
VEGFA 38 79.96 40.5
TP53 38 97.06 40.5
IL6 36 85.29 39.5
CASP3 36 65.39 39.5
JUN 36 66.26 39.5
MMP9 35 50.32 39.0
STAT3 35 47.80 39.0
TNF 35 38.35 39.0
MAPK8 35 40.74 39.0
PTGS2 33 38.68 38.0
Open in a new tab

CASP3 = caspase3, IL6 = interleukin-6, JUN = transcription factor AP-1, MAPK8 = mitogen-activated protein kinase 8, MMP9 = matrix metallo protein, PTGS2 = prostaglandin endoperoxidase 2, STAT3 = activator of transcription 3, TP53 = tumor protein p53, TNF = tumor necrosis factor, VEGFA = vascular endothelial growth factor A.

3.3. GO functional enrichment analysis results

Screening was conducted according to the criterion that the corrected P value was less than .05, and a total of 313 GO functional items were enriched in BP (284), MF (58), and CC (28) items, respectively. Among them, BP is mainly involved in positive regulation of apoptotic process, response to drug, positive regulation of gene expression, negative regulation of apoptotic process, apoptotic process, positive regulation of transcription from RNA polymerase II promoter, inflammatory response, negative regulation of cell proliferation, positive regulation of cell proliferation, response to lipopolysaccharide etc. CC is mainly involved incytoplasm, cytosol, nucleus, nucleoplasm, plasma membrane, extracellular space, extracellular region, macromolecular complex, extracellular exosome, mitochondrion etc. MF is mainly involved in protein binding, identical protein binding, enzyme binding, protein kinase binding, protein homodimerization activity, macromolecular complex binding, peptidase activity, cytokine activity, ubiquitin protein ligase binding, transcriptional activator activity etc. The bubble plot of the GO functional enrichment analysis (top 20 after correction P value) is shown in Figure 4.

Figure 4.

Figure 4.

Open in a new tab

Bar plot of GO functional enrichment analysis. GO = gene ontology.

3.4. KEGG pathway enrichment analysis results

Screening was performed according to the standard that the corrected P value was less than .05, and a total of 126 KEGG signaling pathways were enriched. The visual display results of the top 20 items with the corrected P value are shown in Figure 5, and the specific information is shown in Table 2. It was showed that the potential targets of ursolic acid in the treatment of OP mainly include hepatitis B, TNF signaling pathway, pathways in cancer, human cytomegalovirus infection (HTLV), AGE-RAGE signaling pathway in diabetic complications, IL-17 signaling pathway, apoptosis, human T-cell leukemia virus 1 infection, pancreatic cancer, pathogenic Escherichia coli infection, colorectal cancer, relaxin signaling pathway, prostate cancer, platinum drug resistance and many other pathways.

Figure 5.

Figure 5.

Open in a new tab

Bubble diagram of KEGG pathway enrichment analysis. KEGG = kyoto encyclopedia of genes and genomes.

Table 2.

KEGG enrichment analysis results of ursolic acid for OP treatment.

KEGG ID Pathway name Gene number P value
hsa05417 Lipid and atherosclerosis 24 4.32E-26
hsa05167 Kaposi sarcoma-associated herpesvirus infection 21 4.12E-22
hsa05161 Hepatitis B 19 2.10E-20
hsa05162 Measles 18 5.68E-20
hsa04668 TNF signaling pathway 17 6.62E-20
hsa05200 Pathways in cancer 26 1.14E-19
hsa05163 Human cytomegalovirus infection 19 8.52E-18
hsa04933 AGE-RAGE signaling pathway in diabetic complications 15 2.72E-17
hsa04657 IL-17 signaling pathway 14 5.23E-16
hsa04210 Apoptosis 15 2.41E-15
hsa05169 Epstein-Barr virus infection 16 2.71E-14
hsa05418 Fluid shear stress and atherosclerosis 14 9.92E-14
hsa05222 Small cell lung cancer 12 6.67E-13
hsa05166 Human T-cell leukemia virus 1 infection 15 2.24E-12
hsa05212 Pancreatic cancer 11 3.16E-12
hsa05130 Pathogenic Escherichia coli infection 14 9.04E-12
hsa05210 Colorectal cancer 11 1.13E-11
hsa04926 Relaxin signaling pathway 12 2.90E-11
hsa05215 Prostate cancer 11 3.86E-11
hsa01524 Platinum drug resistance 10 7.93E-11
Open in a new tab

KEGG = kyoto encyclopedia of genes and genomes, OP = osteoporosis, TNF = tumor necrosis factor.

3.5. Molecular docking results of component-core target protein

The binding energies (docking affinity) of ursolic acid to core target proteins tumor protein p53 (TP53), transcription factor AP-1 (JUN), interleukin- 6 (IL6), vascular endothelial growth factor A (VEGFA), CASP3, and mitogen-activated protein kinase (MAPK8) were −10.5, −9.8, −10.6, −10.6, −10.5, −11.5 kcal/mol (1 kcal = 4.186 kJ), respectively (Table 3). Both of binding energies were lower than −5 kacl/mol, which indicating that ursolic acid has a strong binding activity to the protein by the core target gene. The results of molecular docking between ursolic acid and the protein by the core target gene (the top 6 in binding energy) are shown in Figure 6.

Table 3.

The results of molecular docking.

Compound Target PDB Energy (kcal/mol)
Ursolic acid CASP3 1cp3 −10.5
Ursolic acid IL6 1alu −10.6
Ursolic acid MAPK8 1ukh −11.5
Ursolic acid JUN 1a02 −9.8
Ursolic acid TP53 1a1u −10.5
Ursolic acid VEGFA 1bj1 −10.6
Open in a new tab

CASP3 = caspase3, IL6 = interleukin-6, JUN = transcription factor AP-1, MAPK8 = mitogen-activated protein kinase 8, PDB = protein data bank, TP53 = tumor protein p53, VEGFA = vascular endothelial growth factor A.

Figure 6.

Figure 6.

Open in a new tab

Molecular docking of ursolic acid with 6 core target genes.

4. Discussion and conclusion

OP is a systemic bone disease characterized by progressive loss of bone mass, fragility, and susceptibility to fractures.[18] According to the results of the first epidemiological survey of OP in China, OP has become an important health problem in the middle-aged and elderly population in my country. The prevalence of OP in people over 50 years old is 19.2%, the prevalence of OP in China has reached 51.6%, which seriously affects the quality of life of the elderly.[19] Therefore, the related research of OP has attracted more and more attention by scholars. The current clinical drug treatment for OP is still dominated by chemical drugs, including estrogen, selective estrogen receptor modulators, bisphosphonates, calcitonin, and bone formation promoters.[20] Previous study showed that the extensive use of chemical drugs causing a certain degree of kidney damage as well as serious side effects such as induction of breast cancer and endometrial cancer, which restricts its clinical application.[21] TCM has significant effects in the treatment of various diseases, and has few side effects, and is especially suitable for the treatment of senile diseases with declining renal metabolic function.[22] Therefore, TCM exhibits broad potential and application prospects in preventing and treating kidney injury and improving OP. Ursolic acid belongs to ursane-type pentacyclic triterpenoids, which exist in natural medicines such as bearberry, privet lucidum, wild rose hip, hedyotis diffusa, plantain, etc. It exhibits various effects biological function which has been used for many years.[23] Compared with a series of adverse reactions such as renal injury caused by chemical drugs in the treatment of OP, ursolic acid has obvious improvement effect on renal injury.[24] It was believed that the kidney stores the essence, and the essence produces the marrow in TCM. The marrow resides in the bone cavity to nourish the bones. When the kidney essence is deficient, the bones wither and the marrow decreases. Therefore, the kidneys play a crucial role in the growth and development of bones in “kidney governing bones” theory.[25] From the above research results and the theory of TCM, it was revealed that ursolic acid has the potential in treatment of OP. In thie present study, a total of 52 ursolic acid-related target genes and 4657 OP-related target genes were excavated. Through venn diagram analysis, 43 common target genes of component-disease were obtained. The PPI network of the above common target genes shows that the target genes are interconnected and interact with each other; the network topology analysis results show that the core target genes of ursolic acid in the treatment of OP mainly include P53, VEGFA, IL6, TNF, CASP3, MMP9, JUN, STAT3, MAPK8, and PTGS2, etc. The occurrence and development of OP is closely related to a variety of inflammatory cytokines. Some studies have pointed out that IL-6 and TNF-α have been confirmed as important inflammatory cytokines involved in bone resorption, which can promote bone resorption and aggravate the disease development of patients.[26] Among them, IL-6 is a multi-effect inflammatory cytokine that may participate in multiple processes such as inflammatory response, immune response, hematopoietic regulation and tumorigenesis.[27] Previous studies have shown that IL-6 may regulate the apoptosis and differentiation of osteoblasts through various signaling pathways, and promote the formation of osteoclasts, thereby promoting bone resorption and ultimately leading to the occurrence of OP.[28] In addition, it was reported that IL-6 may also induce and activate the signal transducer and activator of transcription 3 (STAT3), MAPK and intracellular phosphatidylinositol kinase (PI3K), and these 3 factors are closely related to the occurrence and development of OP.[29–31] It was revealed that TNF-α may not only induce the expression of nuclear factor kappa B (NF-κB) receptor activator ligand (RANKL) in osteoblasts, but also directly act on RANKL to induce the formation of osteoclasts and promote bone resorption.[32] It was found that ursolic acid may protects reduce the levels of cytokines TNF-α and IL-1β that against ulcerative colitis via anti-inflammatory and antioxidant effects in mice.[33] The above researches suggests that IL-6 and TNF-α are potential targets of ursolic acid in the treatment of OP.

MAPK8 is a member of the MAPK family and plays an important role in regulating inflammatory and immune responses. On the one hand, MAPK plays an important role in the formation and activation of osteoclasts that affect the development of OP by mediating the NF-κB signaling pathway.[34] On the other hand, activated MAPK may promote the generation of osteoblasts, thus improving the symptoms of OP.[35] Prostaglandins induce macrophage colony-stimulating factor (M-CSF) and RANKL expression, and also promote osteoclast differentiation and inhibit osteocyte function.[36] Prostaglandin endoperoxidase 2 (PTGS2) is the rate-limiting enzyme in the production of prostaglandins and has a certain inhibitory effect on the above-mentioned activities of prostaglandins.[37] Vascular endothelial growth factor (VEGF) both supports angiogenesis and promotes the function of osteoblasts that may partially regulate the functions of osteoblasts and osteoclasts through autocrine, endocrine and paracrine mechanisms, and promote bone formation and reduction of bone resorption.[38] The caspase family is a key factor in regulating the process of apoptosis, among which caspase 3 is one of the most critical apoptotic effectors in this family and is considered to be the executor of apoptosis. When caspase 3 is activated, apoptosis cannot be reversed.[39] In the present study, through the GO functional annotation analysis of shared targets, it was found that GO biological processes were mainly concentrated in the process of apoptosis, regulation of cell proliferation, and drug response. Through the KEGG pathway enrichment analysis of common target genes, it was revealed that they were mainly enriched in tumor pathway, TNF signaling pathway, hepatitis B, PI3K/Akt signaling pathway, human HTLV-I infection and other pathways. Among them, the PI3K/Akt signaling pathway is closely related to bone tissue metabolism.[40] Activation of the PI3K/Akt signaling pathway may stimulate the proliferation and differentiation of osteoblasts while inhibiting their apoptosis. In addition, PI3K can stimulate the formation of osteoclast actin filaments, regulate cell chemotaxis, attachment and proliferation, and inhibit the PI3K expression reduces bone resorption by mature osteoclasts.[41] Previous studies have been confirmed that ursolic acid can inhibit the conduction of PI3K/Akt signaling pathway, resulting in up-regulation of downstream pro-apoptotic protein expression, activation of endoplasmic reticulum stress pathway, and ultimately promoting cell apoptosis.[42] Relevant studies have confirmed that there is a close relationship between chronic hepatitis B virus infection and OP, and its mechanism of action may be related to the chronic inflammation caused by the virus infection.[43] Hepatitis B virus infection can induce the secretion of inflammatory cytokines such as TNF-α, IL-1, and IL-6, which can increase the expression of RANKL and stimulate bone resorption.[44] The combined effect of the above-mentioned inflammatory cytokines is the main cause of OP caused by chronic hepatitis B virus infection, which can lead to decreased bone formation and increased bone resorption, thereby reducing bone mineral density.[45] In addition, HBV infection inhibits hepatic 25-hydroxyvitamin D production and vitamin D uptake, thereby increasing bone loss and reducing bone formation.[46] Hepatic decompensation caused by long-term hepatitis B virus infection affects collagen synthesis in bone matrix by inhibiting fibroblast growth, and may co-suppress osteoblast function by increasing the expression of carcinoembryonic fibronectin.[47]

In the present study, molecular docking technology was used to verify the molecular docking between ursolic acid and the encoded proteins of core target genes TP53, JUN, IL6, VEGFA, CASP3, and MAPK8. The results showed that ursolic acid has strong docking activity with the above-mentioned core target gene-encoded protein (the binding energy is less than −5.0kcal/mol), which further indicates that ursolic acid can interact with the core target gene-encoded protein receptor. Stable binding and play its role in the treatment of OP. The results preliminarily verified the reliability of the above-mentioned network pharmacological prediction results, and laid a foundation for the subsequent research on the mechanism of action of ursolic acid in the treatment of OP.

Taken together, the therapeutic effect of ursolic acid on OP may be through the regulation of core target genes such as P53, VEGFA, IL6, TNF, CASP3, MMP9, JUN, STAT3, MAPK8, and PTGS2. It may mainly related to cancer pathways, hepatitis B signaling pathway, TNF signaling pathway and many other key pathways. Its mechanism may involves multiple therapeutic targets and signaling pathways, reflecting the characteristics of TCM for treating diseases with multiple targets and multiple pathways. However, the potential targets and pathways of ursolic acid in the treatment of OP predicted in the present study still need to be further verified by relevant experiments.

Acknowledgments

Shuqing Zhou and Jingxin Mao conceived and designed the research. Jingxin Mao, Bowen Yang, and Qiuwen Zhu carried out the analysis and wrote the paper in the study. Shuqing Zhou and Jingxin Mao make the equally contribution to the manuscript. All authors declare that there have not any commercial or associative interest that represents competing interests in connection with the work submitted.

Author contributions

Conceptualization: Jingxin Mao, Shuqing Zhou.

Data curation: Bowen Yang, Qiuwen Zhu, Jingxin Mao.

Formal analysis: Bowen Yang, Xiaodong Wang.

Funding acquisition: Jingxin Mao.

Investigation: Bowen Yang.

Methodology: Bowen Yang.

Resources: Qiuwen Zhu, Jingxin Mao, Shuqing Zhou.

Software: Qiuwen Zhu, Xiaodong Wang.

Supervision: Qiuwen Zhu, Jingxin Mao, Shuqing Zhou.

Validation: Qiuwen Zhu, Xiaodong Wang, Jingxin Mao.

Visualization: Qiuwen Zhu, Xiaodong Wang, Shuqing Zhou.

Writing – original draft: Bowen Yang.

Writing – review & editing: Jingxin Mao.

Abbreviations:

BP =
biological process
CASP3 =
caspase3
CC =
cellular component
GO =
gene ontology
HTLV =
human cytomegalovirus infection
IL6 =
interleukin-6
JUN =
transcription factor AP-1
KEGG =
kyoto encyclopedia of genes and genomes
MAPK8 =
mitogen-activated protein kinase 8
M-CSF =
macrophage colony-stimulating factor
MF =
molecular function
MMP9 =
matrix metallo protein
NF-κB =
nuclear factor kappa B
OP =
osteoporosis
PI3K =
intracellular phosphatidylinositol kinase
PPI =
protein-protein interaction
PTGS2 =
prostaglandin endoperoxidase 2
RANKL =
receptor activator ligand
STAT3 =
activator of transcription 3
TCM =
traditional chinese medicine
TNF =
tumor necrosis factor
TP53 =
tumor protein p53
VEGF =
vascular endothelial growth factor
VEGFA =
vascular endothelial growth factor A

This work was supported by 2020 Ministerial Project of China (No. 2020YYCXCQSJ050), the Project of Science and Technology Bureau of Jiangjin District, Chongqing (No. Y2020062) and Scientific and Technological Research Program of Chongqing Municipal Education Commission (KJQN201802705) respectively.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

The authors have no conflicts of interest to disclose.

SZ and JM contributed equally to this work.

How to cite this article: Yang B, Zhu Q, Wang X, Mao J, Zhou S. Using network pharmacology and molecular docking verification to explore the mechanism of ursolic acid in the treatment of osteoporosis. Medicine 2022;101:49(e32222).

Contributor Information

Bowen Yang, Email: bokyoung1983@163.com.

Qiuwen Zhu, Email: zhuqiuwen2022@163.com.

Xiaodong Wang, Email: 1452871935@qq.com.

References

  • [1].Zou Z, Liu W, Cao L, et al. Advances in the occurrence and biotherapy of osteoporosis. Biochem Soc Trans. 2020;48:1623–36. [DOI] [PubMed] [Google Scholar]
  • [2].Sözen T, Özişik L, Başaran NC. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4:46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [3].Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf. 2007;30:755–63. [DOI] [PubMed] [Google Scholar]
  • [4].Zhang N-D, Han T, Huang B-K, et al. Traditional Chinese medicine formulas for the treatment of osteoporosis: implication for antiosteoporotic drug discovery. J Ethnopharmacol. 2016;189:61–80. [DOI] [PubMed] [Google Scholar]
  • [5].Zhang T, Su J, Wang K, et al. Ursolic acid reduces oxidative stress to alleviate early brain injury following experimental subarachnoid hemorrhage. Neurosci Lett. 2014;579:12–7. [DOI] [PubMed] [Google Scholar]
  • [6].Rai SN, Zahra W, Singh SS, et al. Anti-inflammatory activity of ursolic acid in MPTP-induced parkinsonian mouse model. Neurotox Res. 2019;36:452–62. [DOI] [PubMed] [Google Scholar]
  • [7].Zhao J, Chen J, Liu T, et al. Anti-viral effects of urosolic acid on guinea pig cytomegalovirus in vitro. J Huazhong Univ Sci Technol [Medical Sciences]. 2012;32:883–7. [DOI] [PubMed] [Google Scholar]
  • [8].Zhou M, Yi Y, Liu L, et al. Polymeric micelles loading with ursolic acid enhancing anti-tumor effect on hepatocellular carcinoma. J Cancer. 2019;10:58205820–5831.. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9].Guo W, Xu B, Wang X, et al. The analysis of the anti-tumor mechanism of ursolic acid using connectively map approach in breast cancer cells line MCF-7. Cancer Manag Res. 2020;12:3469–76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10].Zheng H, Feng H, Zhang W, et al. Targeting autophagy by natural product Ursolic acid for prevention and treatment of osteoporosis. Toxicol Appl Pharmacol. 2020;409:115271. [DOI] [PubMed] [Google Scholar]
  • [11].Bacanli M, Aydin S, Anlar HG, et al. Protective effects of ursolic acid in the kidneys of diabetic rats. Turkish J Pharm Sci. 2018;15:166–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12].Li S, Fan T-P, Jia W, et al. Network pharmacology in traditional Chinese medicine. Hindawi: 2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13].Hsin K-Y, Ghosh S, Kitano H. Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology. PLoS One. 2013;8:e83922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [14].Momota R, Ohtsuka A. Network of anatomical texts (NAnaTex), an open-source project for visualizing the interaction between anatomical terms. Anat Sci Int. 2018;93:149–53. [DOI] [PubMed] [Google Scholar]
  • [15].Makarov VV, Zhuravlev MO, Runnova AE, et al. Betweenness centrality in multiplex brain network during mental task evaluation. Phys Rev E. 2018;98:062413. [Google Scholar]
  • [16].Cohen E, Delling D, Pajor T, et al. Computing classic closeness centrality, at scale. 2014:37–50. [Google Scholar]
  • [17].Gilson MK, Honig B. Calculation of the total electrostatic energy of a macromolecular system: solvation energies, binding energies, and conformational analysis. Proteins Struct Funct Bioinf. 1988;4:7–18. [DOI] [PubMed] [Google Scholar]
  • [18].Coll PP, Phu S, Hajjar SH, et al. The prevention of osteoporosis and sarcopenia in older adults. J Am Geriatr Soc. 2021;69:1388–98. [DOI] [PubMed] [Google Scholar]
  • [19].Baccaro LF, Conde DM, Costa-Paiva L, et al. The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil. Clin Interv Aging. 2015;10:583–91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [20].Liu GF, Wang ZQ, Liu L, et al. A network meta‐analysis on the short‐term efficacy and adverse events of different anti‐osteoporosis drugs for the treatment of postmenopausal osteoporosis. J Cell Biochem. 2018;119:4469–81. [DOI] [PubMed] [Google Scholar]
  • [21].Whayne TF. Hypertriglyceridemia: an infrequent, difficult-to-predict, severe metabolic and vascular problem associated with estrogen administration. Curr Vasc Pharmacol. 2020;18:254–61. [DOI] [PubMed] [Google Scholar]
  • [22].An J, Yang H, Zhang Q, et al. Natural products for treatment of osteoporosis: the effects and mechanisms on promoting osteoblast-mediated bone formation. Life Sci. 2016;147:46–58. [DOI] [PubMed] [Google Scholar]
  • [23].Seo DY, Lee SR, Heo J-W, et al. Ursolic acid in health and disease. Korean J Physiol Pharmacol. 2018;22:235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [24].Zhao J, Zheng H, Sui Z, et al. Ursolic acid exhibits anti-inflammatory effects through blocking TLR4-MyD88 pathway mediated by autophagy. Cytokine. 2019;123:154726. [DOI] [PubMed] [Google Scholar]
  • [25].Ju D, Liu M, Zhao H, et al. Mechanisms of “kidney governing bones” theory in traditional Chinese medicine. Front Med. 2014;8:389–93. [DOI] [PubMed] [Google Scholar]
  • [26].Lin C-C, Li T-C, Liu C-S, et al. Associations of TNF-α and IL-6 polymorphisms with osteoporosis through joint effects and interactions with LEPR gene in Taiwan: Taichung Community Health Study for Elders (TCHS-E). Mol Biol Rep. 2016;43:1179–91. [DOI] [PubMed] [Google Scholar]
  • [27].Sang C, Zhang J, Zhang Y, et al. TNF‐α promotes osteoclastogenesis through JNK signaling‐dependent induction of Semaphorin3D expression in estrogen‐deficiency induced osteoporosis. J Cell Physiol. 2017;232:3396–408. [DOI] [PubMed] [Google Scholar]
  • [28].Blaschke M, Koepp R, Cortis J, et al. IL-6, IL-1β, and TNF-α only in combination influence the osteoporotic phenotype in Crohn’s patients via bone formation and bone resorption. 2018. [DOI] [PubMed] [Google Scholar]
  • [29].Chen L, Zhang R-Y, Xie J, et al. STAT3 activation by catalpol promotes osteogenesis-angiogenesis coupling, thus accelerating osteoporotic bone repair. Stem Cell Res Ther. 2021;12:1–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30].Xing L-Z, Ni H-J, Wang Y-l. Quercitrin attenuates osteoporosis in ovariectomized rats by regulating mitogen-activated protein kinase (MAPK) signaling pathways. Biomed Pharmacother. 2017;89:1136–41. [DOI] [PubMed] [Google Scholar]
  • [31].Xi J-C, Zang H-Y, Guo L-X, et al. The PI3K/AKT cell signaling pathway is involved in regulation of osteoporosis. J Recept Signal Transduct. 2015;35:640–5. [DOI] [PubMed] [Google Scholar]
  • [32].Fu SC, Wang P, Qi MX, et al. The associations of TNF‐α gene polymorphisms with bone mineral density and risk of osteoporosis: a meta‐analysis. Int J Rheum Dis. 2019;22:1619–29. [DOI] [PubMed] [Google Scholar]
  • [33].Liu B, Piao X, Guo L, et al. Ursolic acid protects against ulcerative colitis via anti-inflammatory and antioxidant effects in mice. Mol Med Rep. 2016;13:4779–85. [DOI] [PubMed] [Google Scholar]
  • [34].Zhu J, Jiang L, Liu Y, et al. MAPK and NF-κB pathways are involved in bisphenol A-induced TNF-α and IL-6 production in BV2 microglial cells. Inflammation. 2015;38:637–48. [DOI] [PubMed] [Google Scholar]
  • [35].Kim HK, Kim M-G, Leem K-H. Osteogenic activity of collagen peptide via ERK/MAPK pathway mediated boosting of collagen synthesis and its therapeutic efficacy in osteoporotic bone by back-scattered electron imaging and microarchitecture analysis. Molecules. 2013;18:15474–89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [36].Udagawa N, Koide M, Nakamura M, et al. Osteoclast differentiation by RANKL and OPG signaling pathways. J Bone Miner Metab. 2021;39:19–26. [DOI] [PubMed] [Google Scholar]
  • [37].Cui J, Jia J. Natural COX-2 inhibitors as promising anti-inflammatory agents: an update. Curr Med Chem. 2021;28:3622–46. [DOI] [PubMed] [Google Scholar]
  • [38].Clarkin CE, Gerstenfeld LC. VEGF and bone cell signalling: an essential vessel for communication? Cell Biochem Funct. 2013;31:1–11. [DOI] [PubMed] [Google Scholar]
  • [39].Asadi M, Taghizadeh S, Kaviani E, et al. Caspase‐3: structure, function, and biotechnological aspects. Biotechnol Appl Biochem. 2022;69:1633–45. [DOI] [PubMed] [Google Scholar]
  • [40].Li H, Li T, Fan J, et al. miR-216a rescues dexamethasone suppression of osteogenesis, promotes osteoblast differentiation and enhances bone formation, by regulating c-Cbl-mediated PI3K/AKT pathway. Cell Death Diff. 2015;22:1935–45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [41].Lu J, Ye C, Huang Y, et al. Corilagin suppresses RANKL‐induced osteoclastogenesis and inhibits oestrogen deficiency‐induced bone loss via the NF‐κB and PI3K/AKT signalling pathways. J Cell Mol Med. 2020;24:10444–57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [42].Sun X-H, Wang X, Zhang Y, et al. Exosomes of bone-marrow stromal cells inhibit cardiomyocyte apoptosis under ischemic and hypoxic conditions via miR-486-5p targeting the PTEN/PI3K/AKT signaling pathway. Thromb Res. 2019;177:23–32. [DOI] [PubMed] [Google Scholar]
  • [43].Chen S-J, Lin C-S, Lin C-L, et al. Osteoporosis is associated with high risk for coronary heart disease: a population-based cohort study. Medicine. 2015;94:e1146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [44].Gonzalez-Calvin JL, Gallego-Rojo F, Fernandez-Perez R, et al. Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab. 2004;89:4325–30. [DOI] [PubMed] [Google Scholar]
  • [45].Chang K-H, Chang M-Y, Muo C-H, et al. Exposure to air pollution increases the risk of osteoporosis: a nationwide longitudinal study. Medicine. 2015;94:e733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [46].Chen C-H, Lin C-L, Kao C-H. Association between chronic hepatitis B virus infection and risk of osteoporosis: a nationwide population-based study. Medicine. 2015;94:e2276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [47].Nakchbandi IA. Osteoporosis and fractures in liver disease: relevance, pathogenesis and therapeutic implications. World J Gastroenterol. 2014;20:9427–38. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Medicine are provided here courtesy of Wolters Kluwer Health

RESOURCES